Research Article

Ferulic Acid Attenuates TGF-β1-Induced Renal Cellular Fibrosis in NRK-52E Cells by Inhibiting Smad/ILK/Snail Pathway

Ming-gang Wei, 1 Wei Sun, 2 Wei-ming He, 2 Li Ni, 1 and Yan-yu Yang 1

1The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China
2Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing, Jiangsu 210029, China

Correspondence should be addressed to Ming-gang Wei; weiminggang@suda.edu.cn

Received 19 January 2015; Accepted 18 March 2015

Academic Editor: Mariangela Rondanelli

Copyright © 2015 Ming-gang Wei et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Renal fibrosis is a common cause of renal dysfunction with chronic kidney disease. Central to this process is epithelial-mesenchymal transformation (EMT) of proximal tubular epithelial cells driven by transforming growth factor-β1 (TGF-β1) signaling. The present study aimed to investigate the effect of Ferulic acid (FA) on EMT of renal proximal tubular epithelial cell line (NRK-52E) induced by TGF-β1 and to elucidate its underlying mechanism against EMT related to TGF-β1/Smads pathway. The NRK-52E cells were treated for 48 h with TGF-β1 (5 ng/mL) in different concentrations of FA (0 to 200 μM). Fibronectin, a mesenchymal marker, was assessed by western blotting. Western blotting was also used to examine the EMT markers (E-cadherin, and α-smooth muscle actin (α-SMA)), signal transducer (p-Smad2/3), and EMT initiator (Snail). ILK was also assayed by western blotting. The results showed that TGF-β1 induced spindle-like morphological transition in NRK-52E cells. Smad2/3 signaling pathway activation, increased fibronectin, α-SMA, ILK, and Snail expression, and decreased E-cadherin expression in TGF-β1-treated NRK-52E cells. FA efficiently blocked P-Smad2/3 activation and attenuated all these EMT changes induced by TGF-β1. These findings suggest that FA may serve as a potential fibrosis antagonist for renal proximal tubule cells by inhibiting EMT process.

1. Introduction

Renal fibrosis, characterized by glomerulosclerosis and tubulointerstitial fibrosis, is the final common manifestation of various chronic kidney diseases (CKD), and progressive accumulation and deposition of extracellular matrix (ECM) proteins in the interstitial area are a key feature. The pathogenesis of renal fibrosis is a progressive process that ultimately leads to end-stage renal failure [1–4].

The role of epithelial-to-mesenchymal transition (EMT) of renal tubular epithelial cells has been implicated in accelerating fibrogenesis [5, 6]. Among the many fibrogenic factors that regulate renal fibrotic process, transforming growth factor-β1 (TGF-β1) has been identified as the most potent mediator and convergent pathway in inducing EMT and renal fibrosis, mainly via the TGF-β1/Smads signal transduction pathway [7–11]. EMT is a complex process that involves cytoskeletal remodeling, cell-cell and cell-matrix adhesion, and transcriptional regulation, leading to the transition from a polarized epithelial phenotype to an elongated fibroblastoid phenotype and changes in transcriptional regulation to increase cell mobility and invasion [9, 12]. In the process of EMT, a significant decrease in E-cadherin and an increase in α-smooth muscle actin (α-SMA) expression have been demonstrated for years concomitantly with the increase in Snail protein [5, 13]. Snail is a zinc finger transcriptional factor, functions as a regulator to suppress the expression of adhesion molecules during EMT [14, 15]. The most common biochemical change associated with EMT is the loss of E-cadherin expression regulated by Snail [15]. ILK is well documented as a key intracellular mediator that promotes EMT in different cell systems including tubular epithelial cells [16–19]. Although the molecular details by which ILK induces EMT remain to be elucidated, it seems to be related to its ability to induce key EMT-regulatory gene Snail expression. In concert, the ILK/Snail signaling plays a key role in mediating EMT [18].
Ligusticum chuanxiong has been used in traditional Chinese medicine (TCM) for many years. The clinical effectiveness of Ligusticum on chronic renal failure has been evaluated in clinical trials [20]. It can reduce 24-hour urinary protein excretion, ameliorate renal pathological changes, slow down, and even halt the progression of chronic renal failure. Ferulic acid (4-hydroxy-3-methoxycinnamic acid) (FA), an effective component of Ligusticum chuanxiong, is a ubiquitous phenolic acid in the plant kingdom [21]. FA exhibits many physiological functions, including antioxidant, anti-inflammatory, and anticancer activities [22–24]. We previously reported that the Qiguiyishen decoction reduced adriamycin-induced nephropathy. FA is one of the most effective components of the Qiguiyishen decoction [25]. However, the antifibrosis effects of FA remain unclear. In this study, we use the in vitro model to investigate the effect of FA in TGF-β-induced proximal tubular fibrosis. This study finds that FA plays a role in the regulation of renal fibrosis by inhibiting TGF-β-induced renal fibrosis possibly through Smad/ILK/Snail pathway and may lead to possible therapeutic interventions to suppress EMT and renal fibrosis.

2. Materials and Methods

2.1. Drug and Reagents. Ferulic acid was purchased from Tauto Biotech (Shanghai, China) (purity not less than 98%). Ferulic acid was dissolved in DMSO for its administration. Other chemicals used in this study were of analytical or higher grade.

2.2. Cell Culture and Treatment. NRK-52E cells were purchased from the Institute of Biochemistry and Cell Biology (Shanghai, China) and cultured in DMEM/F12 (Gibco, USA) with 10% fetal bovine serum (FBS) (Gibco, USA) in an atmosphere of 5% CO₂ at 37°C. To determine the effects of FA treatment on the EMT, NRK-52E cells were incubated into 6-well plates with 50–60% confluence, starved for 24 h by incubation with DMEM/F12 containing 0.5% FBS, and then divided into following groups: (1) normal control group incubated in DMEM/F12 containing 0.1% DMSO (i.e., vehicle); (2) TGF-β1 group stimulated with recombinant TGF-β1 (5 ng/mL; Peprotech); and (3) FA-treated groups stimulated with recombinant TGF-β (5 ng/mL) and simultaneously treated with different concentrations of FA (25, 50, 100, and 200 μM). After 48 h, cells were harvested and processed for western blot analysis.

2.3. Western Blotting. Western blot assays were used to evaluate the expression of the protein levels. Briefly, cells were lysed in lysis buffer (20 mM Tris, 1 mM EDTA, 1% Triton X-100, 1 mM Na₃VO₄, 20 mg/mL Aprotinin, 20 mg/mL Leupeptin, 1 mM DTT, and 1 mM PMSF) and the crude protein lysate was resolved by 12% SDS-PAGE. After protein transfers to a polyvinylidene difluoride (PVDF) membrane and the PVDF membrane was blocked with 5% (w/v) nonfat milk in tris-buffered saline (TBST) for 1 h at 37°C. The blots were probed with a dilution of primary antibody. The primary antibodies used were as follows: antifibronectin (ab23751, Abcam, Cambridge, UK), anti-pSmad2/3 (ab63399, Abcam, Cambridge, UK), anti-Smad2/3 (ab63672, Abcam, Cambridge, UK), anti-E-cadherin (ab133597, Abcam, Cambridge, UK), anti-ILK (ab137912, Abcam, Cambridge, UK), anti-snail (ab180714, Abcam, Cambridge, UK), anti-Smad2/3 (ab63399, Abcam, Cambridge, UK), anti-α-SMA (ab5694, Abcam, Cambridge, UK), anti-ILK (ab137912, Abcam, Cambridge, UK), anti-snail (ab180714, Abcam, Cambridge, UK), and β-actin (Santa Cruz Biotechnology, Inc.). After hybridization, the blots were washed and hybridized with 1:5000 (v/v) dilutions of goat antirabbit IgG, horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology, Inc.). The signal was generated by adding enhanced Chemiluminescent reagent. β-actin was used as an internal control.

2.4. Statistics. Data are shown as means ± standard deviation (SD). The statistical difference between groups was determined by the paired Student’s t-test. A P value less than 0.05 was considered significant.

3. Results

3.1. FA Reversed TGF-β1-Induced Morphological Changes in NRK-52E Cells. Phase-contrast microscopy showed that the cells displayed a pebble-like appearance in the control group. The cells adopted an elongated, fibroblast-like phenotype after the stimulation with recombinant TGF-β1. Most importantly, concentrations higher than 50 μM FA attenuated TGF-β1-induced the morphological changes mentioned above (Figure 1).

3.2. FA Reversed TGF-β1-Induced Expression of Fibronectin in NRK-52E Cells. To evaluate the regulatory effects of FA in TGF-β1-induced ECM proteins accumulation, the expression of fibronectin was examined by western blotting. Following the treatment with TGF-β1, the expression levels of fibronectin in NRK-52E cells was upregulated compared with the control. FA treatment significantly decreased the production of fibronectin in a dose-dependent manner in NRK-52E cells compared with TGF-β1-treated group (Figure 2).

3.3. FA Reversed TGF-β1-Induced EMT in NRK-52E Cells. To confirm the effect of FA on the EMT in NRK-52E cells, the expression of the epithelial marker E-cadherin, and the mesenchymal marker α-SMA were examined by western blotting. As shown in Figure 3, exposure of cells to TGF-β1 resulted in a significant reduction in E-cadherin and an increase in α-SMA, compared with control. FA significantly prevented TGF-β1 stimulated changes of E-cadherin expression at 100 μM and α-SMA expression at 25 μM. These results suggest that FA prevents the loss of the epithelial marker Ecadherin and the de novo expression of myofibroblast marker α-SMA in renal epithelial cells stimulated by TGF-β1.

3.4. FA Attenuates TGF-β1 Signaling via Smad2/3 Pathway. Activation of smad2/3 by phosphorylation is the central process of the EMT response to TGF-β1 [26]. Exposure to TGF-β1 resulted in significantly increased Smad2/3 phosphorylation, compared with control. FA treatment significantly
Figure 1: FA reversed TGF-β1-induced morphological changes in NRK-52E cells. NRK-52E cells were incubated with 5 ng/mL of TGF-β1 for 48 h with different concentrations of FA (0, 25, 50, 100, and 200 μM). (a) Untreated NRK-52E cells showed that a pebble-like shape is clearly observed. (b) TGF-β1-treated cells showed a decrease in cell-cell contacts and adopt a more elongated morphological shape. (c), (d), (e), and (f) showed reversed TGF-β1-induced morphological changes by different concentrations of FA (magnification of 200x).

Figure 2: Effects of FA on TGF-β1-induced expression of fibronectin in NRK-52E cells. NRK-52E cells were incubated with 5 ng/mL of TGF-β1 for 48 h with different concentrations of FA (0, 25, 50, 100, and 200 μM). (a) The intercellular fibronectin was measured by western blotting with β-actin used as an internal control. (b) The fibronectin was quantitatively analyzed with Image J software. The data showing mean ± SD. *P < 0.05, **P < 0.01, and ***P < 0.005 versus control (0 ng/mL TGF-β1). *P < 0.05, **P < 0.01, and ***P < 0.005 versus control (0 μM FA in the presence of 5 ng/mL TGF-β1).
decreased the phosphorylation of Smad2/3 in a dose-dependent manner in NRK-52E cells compared with TGF-β1-treated group. Concentrations higher than 25 μM significantly blocked Smad2/3 phosphorylation protein expression (Figure 4).

3.5. Effect of FA on the ILK and Snail Expression in NRK-52E Cells. ILK has been shown to be a key intracellular mediator that controls EMT in tubular epithelial cells by inducing key EMT-regulatory gene Snail expression [18]. Because of the association of Snail with EMT, we then investigated the expression of ILK and Snail in NRK-52E cells to underlying mechanism that FA inhibited EMT. As shown in Figure 5, the expression of ILK and Snail in NRK-52E cells was increased in response to TGF-β1 treatment, and the FA markedly decreased TGF-β1-induced ILK and Snail protein expression.

4. Discussion
Renal tubulointerstitial fibrosis is the final consequence of chronic kidney disease which leads to the destruction of the kidney and end-stage renal failure [27, 28]. Renal fibrosis is associated with tubular epithelial cells transition to mesenchymal cells via a process known as EMT. EMT is an important process in the pathogenesis of tubulointerstitial fibrosis and involves a loss of epithelial cell characteristics.
and an increase of mesenchymal cell markers stimulated by various profibrotic cytokines. Therefore, blocking renal EMT may prevent renal fibrosis. TGF-β1 is a well-known profibrotic cytokine in several renal diseases and plays a critical role in the renal EMT process. In this study, we used an in vitro model and NRK-52E cells stimulated by TGF-β1 to address whether FA attenuates renal interstitial fibrosis in vitro and to investigate the underlying mechanisms.

Here we show that exposure to TGF-β1 for 48 h in NRK-52E cells induce morphologic change and an upregulation of ECM protein, fibronectin. TGF-β1 also increases α-SMA and decreases E-cadherin expression in NRK-52E cells. However, FA significantly reverses all of above changes in vitro. These results suggest that FA prevents TGF-β1-mediated renal EMT in vitro. The mechanism by which FA inhibits TGF-β1-induced EMT remains unknown. It is more likely that multiple pathways are involved in the inhibitory effect of FA, among which Smad2/3 activation, ILK, and Snail expression may be the major events during the process. The exact mechanism for the effects of FA on TGF-β1-induced EMT needs to be further elucidated.

TGF-β1 and its downstream signaling pathway were shown to play a critical role in activating cellular pathological mechanisms in renal tubulointerstitial fibrosis through the induction of interstitial cell activation and the expression of several profibrotic genes. It has been demonstrated that activation of TGF-β1 signaling triggers a dramatic induction of Smad2/3 phosphorylation. In this study, we investigated whether it could also block TGF-β1-induced Smad2/3 activation in NRK-52E cells. Our results showed that FA inhibited the p-Smad2/3 activation induced by TGF-β1 in NRK-52E cells. We also further studied the effects of FA on Snail expression, which was the important downstream mediator of TGF-β1/Smads signaling pathway. Our results showed that treatment of FA in NRK-52E cells attenuated TGF-β1-induced upregulation of Snail expression. The present study demonstrated that FA could block TGF-β1-induced EMT probably by inhibition of p-Smad2/3 activation and Snail expression in NRK-52E cells.

Previous studies have shown that ILK is a key intracellular mediator of TGF-β1-induced EMT. TGF-β1 regulation of EMT has been suggested to be dependent on integrin-linked kinase (ILK) function during renal fibrosis [18]. TGF-β1 induced ILK expression in renal tubular epithelial cells is dependent on intracellular Smad signaling. ILK is a widely expressed serine/threonine protein kinase, which localizes to focal adhesion plaques and centrosomes. ILK has a fundamental role in the regulation of cell survival, proliferation, and migration by connecting the cytoplasmic domains of β-integrins to the actin cytoskeleton, mediating integrin signaling in diverse cell types. Together, ILK is a key intracellular mediator of TGF-β1-induced EMT. We further test the effect of FA on the expression level of ILK. As shown in Figure 5, treatment of FA in NRK-52E cells attenuated TGF-β1-induced upregulation of ILK expression. The above observation demonstrated that FA attenuates renal EMT and ECM protein expression in NRK-52E cells induced by TGF-β1. The possible mechanism involves the suppression of
the TGF-β1/Smad2/3 pathway and the subsequent inhibition of ILK and snail expression and inhibition of EMT processes by restoring the expression of E-cadherin in renal proximal tubules.

5. Conclusion

In conclusion, our data present, for the first time, the important information that FA, as an herbal compound, inhibits TGF-β1-induced EMT in NRK-52E cells. These findings may pave the way for an effective therapy for tubulointerstitial fibrosis.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This work was supported by the Grant from the Natural Science Foundation of China (nos. 81273723, 81373604, and 81473633), Jiangsu Administration of Traditional Chinese Medicine (LZ13235), and a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions.
References

[1] P. Boor, T. Ostendorf, and J. Floege, “Renal fibrosis: novel insights into mechanisms and therapeutic targets,” Nature Reviews Nephrology, vol. 6, no. 11, pp. 643–656, 2010.

[2] W. Kriz, B. Kaissling, and M. Le Hir, “Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy?” The Journal of Clinical Investigation, vol. 121, no. 2, pp. 468–474, 2011.

[3] P. Savagner, “Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition,” BioEssays, vol. 23, no. 10, pp. 912–923, 2001.

[4] M. Iwano, D. Plieth, T. M. Danoff, C. Xue, H. Okada, and E. G. Neilson, “Evidence that fibroblasts derive from epithelium during tissue fibrosis,” The Journal of Clinical Investigation, vol. 110, no. 3, pp. 341–350, 2002.

[5] J. Yang and Y. Liu, “Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis,” The American Journal of Pathology, vol. 159, no. 4, pp. 1465–1475, 2001.

[6] J.-M. Fan, Y.-Y. Ng, P. A. Hill et al., “Transforming growth factor-β regulates tubular epithelial-myofibroblast transdifferentiation in vitro,” Kidney International, vol. 56, no. 4, pp. 1455–1467, 1999.

[7] M. K. Phanish, N. A. Wahab, P. Colville-Nash, B. M. Hendry, and M. E. C. Dockrell, “The differential role of Smad2 and Smad3 in the regulation of pro-fibrotic TGF-β1 responses in human proximal-tubule epithelial cells,” Biochemical Journal, vol. 393, no. 2, pp. 601–607, 2006.

[8] J. Zavadil and E. P. Böttiger, “TGF-β and epithelial-to-mesenchymal transitions,” Oncogene, vol. 24, no. 37, pp. 5764–5774, 2005.

[9] B. C. Willis and Z. Borok, “TGF-β-induced EMT: mechanisms and implications for fibrotic lung disease,” American Journal of Physiology: Lung Cellular and Molecular Physiology, vol. 293, no. 3, pp. L525–L534, 2007.

[10] H. Kasai, J. T. Allen, R. M. Mason, T. Kamimura, and Z. Zhang, “TGF-β1 induces human alveolar epithelial to mesenchymal cell transition (EMT),” Respiratory Research, vol. 6, article 56, 2005.

[11] J. Xu, S. Lamouille, and R. Derynck, “TGF-β-induced epithelial to mesenchymal transition,” Cell Research, vol. 19, no. 2, pp. 156–172, 2009.

[12] J. P. Thiery and J. P. Sleeman, “Complex networks orchestrate epithelial-mesenchymal transitions,” Nature Reviews Molecular Cell Biology, vol. 7, no. 2, pp. 131–142, 2006.

[13] M. Veerasamy, T. Q. Nguyen, R. Motazed, A. L. Pearson, R. Goldschmeding, and M. E. C. Dockrell, “Differential regulation of E-cadherin and α-smooth muscle actin by BMP 7 in human renal proximal tubule epithelial cells and its implication in renal fibrosis,” The American Journal of Physiology—Renal Physiology, vol. 297, no. 5, pp. F1238–F1248, 2009.

[14] A. Barrallo-Gimeno and M. A. Nieto, “The Snail genes as inducers of cell movement and survival: implications in development and cancer,” Development, vol. 132, no. 14, pp. 3151–3161, 2005.

[15] W. Jiao, K. Miyazaki, and Y. Kitajima, “Inverse correlation between E-cadherin and Snail expression in hepatocellular carcinoma cell lines in vitro and in vivo,” British Journal of Cancer, vol. 86, no. 1, pp. 98–101, 2002.

[16] Y. Li, J. Yang, C. Dai, C. Wu, and Y. Liu, “Role for integrin-linked kinase in mediating tubular epithelial to mesenchymal transition and renal interstitial fibrogenesis,” Journal of Clinical Investigation, vol. 112, no. 4, pp. 503–516, 2003.

[17] C. Wu, S. Y. Keightley, C. Leung-Hagesteijn et al., “Integrin-linked protein kinase regulates fibronectin matrix assembly, E-cadherin expression, and tumorigenicity,” The Journal of Biological Chemistry, vol. 273, no. 1, pp. 528–536, 1998.

[18] Y. S. Kang, Y. Li, C. Dai, L. P. Kiss, C. Wu, and Y. Liu, “Inhibition of integrin-linked kinase blocks podocyte epithelial-mesenchymal transition and ameliorates proteinuria,” Kidney International, vol. 78, no. 4, pp. 363–373, 2010.

[19] Y. Li, X. Tan, C. Dai, D. B. Stolz, D. Wang, and Y. Liu, “Inhibition of integrin-linked kinase attenuates renal interstitial fibrosis,” Journal of the American Society of Nephrology, vol. 20, no. 9, pp. 1907–1918, 2009.

[20] D. Ren, Y. Tao, and W. Feng, “Effect of Ligusticum on blood endothelial level and renal function in renal failure patients,” Chinese Journal of Integrated Traditional and Western Nephrology, vol. 2, no. 4, pp. 234–235, 2001.

[21] S. Ou and K. C. Kwok, “Ferulic acid: pharmaceutical functions, preparation and applications in foods,” Journal of Science and Food Agriculture, vol. 84, no. 11, pp. 1261–1269, 2004.

[22] M. Srinivasan, A. R. Sudheer, and V. P. Menon, “Ferulic acid: therapeutic potential through its antioxidant property,” Journal of Clinical Biochemistry and Nutrition, vol. 40, no. 2, pp. 92–100, 2007.

[23] J. Kanski, M. Aksenova, A. Stoyanova, and D. A. Butterfield, “Ferulic acid antioxidant protection against hydroxyl and peroxyl radical oxidation in synaptosomal and neuronal cell culture systems in vitro: structure-activity studies,” The Journal of Nutritional Biochemistry, vol. 13, no. 5, pp. 273–281, 2002.

[24] H. Zhu, Q.-H. Liang, X.-G. Xiong et al., “Anti-inflammatory effects of the bioactive compound ferulic acid contained in oldenlandia diffusa on collagen-induced arthritis in rats,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 573801, 10 pages, 2014.

[25] M. Wei, W. Sun, W. He et al., “Qiguiyishen decoction reduced the accumulation of extracellular matrix in the kidneys of rats with adriamycin-induced nephropathy,” Journal of Traditional Chinese Medicine, vol. 34, no. 3, pp. 351–356, 2014.

[26] H. Y. Lan, “Diverse roles of TGF-β1/Smads in renal fibrosis and inflammation,” International Journal of Biological Sciences, vol. 7, no. 7, pp. 1056–1067, 2011.

[27] Y. H. Liu, “Renal fibrosis: new insights into the pathogenesis and therapeutics,” Kidney International, vol. 69, no. 2, pp. 213–217, 2006.

[28] T. D. Hewitson, “Renal tubulointerstitial fibrosis: Common but never simple,” The American Journal of Physiology—Renal Physiology, vol. 296, no. 6, pp. F1239–F1244, 2009.